{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Anaphylaxis & Anaphylactoid Reactions', 'Hepatotoxicity', 'Acute Renal Failure', 'Seizure', 'Stevens Johnson Syndrome/Toxic Epidermal Necrolysis', '9.2.9.', 'Pregnancy', 'Details of all pregnancies in female participants will be collected after the start of', 'study treatment and until the safety follow-up contact/visit.', 'If a pregnancy is reported, the Investigator should inform GSK within 24 hours of', 'learning of the pregnancy and should follow the procedures outlined in Appendix 3.', 'Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth,', 'congenital anomalies, ectopic pregnancy) are considered SAE.', '9.2.10.', 'Medical Device Incidents (Including Malfunctions)', 'Medical devices (spacers/holding chambers) are being provided for use in this study. In', 'order to fulfil regulatory reporting obligations worldwide, the Investigator is responsible', 'for the detection and documentation of events meeting the definitions of incident or', 'malfunction that occur during the study with such devices.', 'The definition of a Medical Device Incident can be found in Appendix 7', 'NOTE: Incidents fulfilling the definition of an AE/SAE will also follow the processes', 'outlined in Section 9.2 and Appendix 6 of the protocol.', '9.2.10.1.', 'Time Period for Detecting Medical Device Incidents', 'Medical device incidents or malfunctions of the device that result in an incident', 'will be detected, documented, and reported during all periods of the study in', 'which the medical device is used.', 'If the Investigator learns of any incident at any time after a participant has been', 'discharged from the study, and such incident is considered reasonably related to', 'a medical device provided for the study, the Investigator will promptly notify', 'the Sponsor.', 'The method of documenting Medical Device Incidents is provided in Appendix', '7.', '9.2.10.2.', 'Follow-up of Medical Device Incidents', 'All medical device incidents involving an AE will be followed and reported in', 'the same manner as other AEs (see Section 9.2). This applies to all participants,', 'including those who discontinue study treatment or the study.', '67']['2017N323364_01', 'CONFIDENTIAL', '2019N398531_00', '207626', 'The Investigator is responsible for ensuring that follow-up includes any', 'supplemental investigations as indicated to elucidate the nature and/or causality', 'of the incident.', 'New or updated information will be recorded on the originally completed form', 'with all changes signed and dated by the Investigator.', '9.2.10.3.', 'Prompt Reporting of Medical Device Incidents to Sponsor', 'Medical device incidents will be reported to the sponsor within 24 hours after', 'the Investigator determines that the event meets the protocol definition of a', 'medical device incident.', 'The Medical Device Incident Report Form will be sent to the sponsor', 'electronically.', 'The same individual will be the contact for the receipt of medical device reports', 'and SAE.', '9.2.10.4.', 'Regulatory Reporting Requirements for Medical Device Incidents', 'The Investigator will promptly report all incidents occurring with any medical', 'device provided for use in the study in order for the sponsor to fulfil the legal', 'responsibility to notify appropriate regulatory authorities and other entities about', 'certain safety information relating to medical devices being used in clinical', 'studies.', 'The Investigator, or responsible person according to local requirements (eg, the', 'head of the medical institution), will comply with the applicable local regulatory', 'requirements relating to the reporting of incidents to the IRB/IEC.', '9.3.', 'Treatment of Overdose', 'An overdose is defined as a dose greater than the total doses described above which', 'results in clinical signs and symptoms. These should be recorded by the Investigator on', 'the AE/SAE eCRF pages. In the event of an overdose of study treatment, the Investigator', 'should use clinical judgment in treating the overdose and contact the GSK medical', 'monitor.', 'GSK is not recommending specific treatment guidelines for overdose and toxicity', 'management. The Investigator is advised to refer to the relevant document(s) for detailed', 'information regarding warnings, precautions, contraindications, adverse events, and other', 'significant data pertaining to the study drug being used in this study. Such documents', 'may include, but not be limited to, the IB or equivalent document provided by GSK.', '9.4.', 'Safety Assessments', 'Planned time points for all safety assessments are provided in the SoA (Section 2).', '68']\n\n###\n\n", "completion": "END"}